Elad Moisseiev1,2, Johnathon D Anderson3, Sharon Oltjen4, Mayank Goswami5, Robert J Zawadzki1,5, Jan A Nolta3, Susanna S Park1. 1. a Department of Ophthalmology and Vision Science , University of California Davis Eye Center , Sacramento , CA , USA. 2. b Sackler School of Medicine , Tel Aviv University , Tel Aviv , Israel. 3. c Stem Cell Program , Institute for Regenerative Cures, UC Davis Medical Center , Sacramento , CA , USA. 4. d Vitreoretinal Research Laboratory, Department of Ophthalmology and Vision Science , University of California Davis Eye Center , Sacramento , CA , USA. 5. e UC Davis RISE Eye-Pod Laboratory, Department of Cell Biology and Human Anatomy , University of California Davis , Davis , CA , USA.
Abstract
PURPOSE: Exosomes derived from human mesenchymal stem cells (hMSCs) cultured under hypoxic conditions contain proteins and growth factors that promote angiogenesis. This study investigated the effect of intravitreal administration of these exosomes on retinal ischemia using a murine model. METHODS: Oxygen-induced retinopathy (OIR) was induced by exposing one-week-old male C57BL/6J mice to 5 days of 75% hyperoxic conditioning, and returning to room air. After hyperoxic conditioning, the right eye of each mouse was injected intravitreally with 1 µl saline or exosomes derived from hMSCs and compared to control mice of the same age raised in room air without OIR injected intravitreally with saline. Two weeks post-injection, fluorescein angiography (FA) and phase-variance optical coherence tomography angiography (pvOCTA) were used to assess retinal perfusion. Retinal thickness was determined by OCT. The extent of retinal neovascularization was quantitated histologically by counting vascular nuclei on the retinal surface. RESULTS: Among eyes with OIR, intravitreal exosome treatment partially preserved retinal vascular flow in vivo and reduced associated retinal thinning; retinal thickness on OCT was 111.1 ± 7.4µm with saline versus 132.1 ± 11.6µm with exosome, p < 0.001. Retinal neovascularization among OIR eyes was reduced with exosome treatment when compared to saline-treated eyes (7.75 ± 3.68 versus 2.68 ± 1.35 neovascular nuclei per section, p < 0.0001). No immunogenicity or ocular/systemic adverse effect was associated with intravitreal exosome treatment. CONCLUSIONS: Intravitreal administration of exosomes derived from hMSCs was well tolerated without immunosuppression and decreased the severity of retinal ischemia in this murine model. This appealing novel non-cellular therapeutic approach warrants further exploration.
PURPOSE: Exosomes derived from human mesenchymal stem cells (hMSCs) cultured under hypoxic conditions contain proteins and growth factors that promote angiogenesis. This study investigated the effect of intravitreal administration of these exosomes on retinal ischemia using a murine model. METHODS:Oxygen-induced retinopathy (OIR) was induced by exposing one-week-old male C57BL/6J mice to 5 days of 75% hyperoxic conditioning, and returning to room air. After hyperoxic conditioning, the right eye of each mouse was injected intravitreally with 1 µl saline or exosomes derived from hMSCs and compared to control mice of the same age raised in room air without OIR injected intravitreally with saline. Two weeks post-injection, fluorescein angiography (FA) and phase-variance optical coherence tomography angiography (pvOCTA) were used to assess retinal perfusion. Retinal thickness was determined by OCT. The extent of retinal neovascularization was quantitated histologically by counting vascular nuclei on the retinal surface. RESULTS: Among eyes with OIR, intravitreal exosome treatment partially preserved retinal vascular flow in vivo and reduced associated retinal thinning; retinal thickness on OCT was 111.1 ± 7.4µm with saline versus 132.1 ± 11.6µm with exosome, p < 0.001. Retinal neovascularization among OIR eyes was reduced with exosome treatment when compared to saline-treated eyes (7.75 ± 3.68 versus 2.68 ± 1.35 neovascular nuclei per section, p < 0.0001). No immunogenicity or ocular/systemic adverse effect was associated with intravitreal exosome treatment. CONCLUSIONS: Intravitreal administration of exosomes derived from hMSCs was well tolerated without immunosuppression and decreased the severity of retinal ischemia in this murine model. This appealing novel non-cellular therapeutic approach warrants further exploration.
Authors: Maria A Bermudez; Ana F Vicente; Maria C Romero; Miguel D Arcos; Jose M Abalo; Francisco Gonzalez Journal: Curr Eye Res Date: 2011-01-28 Impact factor: 2.424
Authors: Ruenn Chai Lai; Fatih Arslan; May May Lee; Newman Siu Kwan Sze; Andre Choo; Tian Sheng Chen; Manuel Salto-Tellez; Leo Timmers; Chuen Neng Lee; Reida Menshawe El Oakley; Gerard Pasterkamp; Dominique P V de Kleijn; Sai Kiang Lim Journal: Stem Cell Res Date: 2010-01-04 Impact factor: 2.020
Authors: Stephanie C Joachim; Martin B Wax; Nils Boehm; Desiree R Dirk; Norbert Pfeiffer; Franz H Grus Journal: Invest Ophthalmol Vis Sci Date: 2011-06-01 Impact factor: 4.799
Authors: Thorsten R Doeppner; Josephine Herz; André Görgens; Jana Schlechter; Anna-Kristin Ludwig; Stefan Radtke; Kyra de Miroschedji; Peter A Horn; Bernd Giebel; Dirk M Hermann Journal: Stem Cells Transl Med Date: 2015-09-03 Impact factor: 6.940
Authors: John C Dreixler; Jacqueline N Poston; Irina Balyasnikova; Afzhal R Shaikh; Kelsey Y Tupper; Sineadh Conway; Venkat Boddapati; Marcus M Marcet; Maciej S Lesniak; Steven Roth Journal: Invest Ophthalmol Vis Sci Date: 2014-04-03 Impact factor: 4.799
Authors: Zeljka Smit-McBride; Krisztina I Forward; Anthony T Nguyen; Matthew H Bordbari; Sharon L Oltjen; Leonard M Hjelmeland Journal: Mol Vis Date: 2014-11-05 Impact factor: 2.367
Authors: Sandra Atienzar-Aroca; Miguel Flores-Bellver; Gemma Serrano-Heras; Natalia Martinez-Gil; Jorge M Barcia; Silvia Aparicio; Daniel Perez-Cremades; Jose M Garcia-Verdugo; Manuel Diaz-Llopis; Francisco J Romero; Javier Sancho-Pelluz Journal: J Cell Mol Med Date: 2016-03-21 Impact factor: 5.310
Authors: Megan R Showalter; Benjamin Wancewicz; Oliver Fiehn; Joehleen A Archard; Shannon Clayton; Joseph Wagner; Peter Deng; Julian Halmai; Kyle D Fink; Gerhard Bauer; Brian Fury; Nicholas H Perotti; Michelle Apperson; Janelle Butters; Peter Belafsky; Gregory Farwell; Maggie Kuhn; Jan A Nolta; Johnathon D Anderson Journal: Biochem Biophys Res Commun Date: 2019-03-26 Impact factor: 3.575
Authors: Yun Lin; Johnathon D Anderson; Lily M A Rahnama; Shenwen V Gu; Anne A Knowlton Journal: Am J Physiol Heart Circ Physiol Date: 2020-09-28 Impact factor: 4.733
Authors: Shannon M Clayton; Joehleen A Archard; Joseph Wagner; D Gregory Farwell; Arnaud F Bewley; Angela Beliveau; Andrew Birkeland; Shyam Rao; Marianne Abouyared; Peter C Belafsky; Johnathon D Anderson Journal: Stem Cells Dev Date: 2020-01-30 Impact factor: 3.272